Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC
June 6th 2022Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.
Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer
Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.
Dabrafenib Plus Trametinib Quadruples Response Rate in BRAF V600+ Pediatric Low-Grade Glioma
The combination of dabrafenib plus trametinib demonstrated a significant improvement in overall response rate, clinical benefit rate, and progression-free survival and fewer grade 3 or greater adverse effects and discontinuations vs carboplatin and vincristine in pediatric patients with low-grade glioma harboring a BRAF V600 mutation.
Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma
June 6th 2022Fixed-dose nivolumab plus relatlimab elicited continued progression-free survival benefit vs nivolumab alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial.
Lurbinectedin Plus Pembrolizumab Produces Early Efficacy Signals in Relapsed Small Cell Lung Cancer
June 6th 2022The combination of lurbinectedin and pembrolizumab demonstrated preliminary efficacy signals and was shown to be tolerable with a median relative dose intensity exceeding 90% in patients with small cell lung cancer that relapsed on platinum-based chemotherapy, according to findings from the phase 1/2 LUPER study.
Key Subgroup Analyses Supports Tafasitamab Plus Lenalidomide for High-Risk R/R DLBCL
Treatment with tafasitamab plus lenalidomide demonstrated trends toward improved overall survival vs systemic regimens across key subgroups of patients with high-risk relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant, according to findings from an observational, retrospective analysis of the cohort RE-MIND2 study.
Larotrectinib Continues to Demonstrate High DCR, Elicit Durable Responses in TRK Fusion+ CNS Tumors
June 5th 2022Larotrectinib continued to produce rapid and durable responses, with a high disease control rate and an acceptable toxicity profile in patients with TRK fusion–positive, primary central nervous system tumors.
Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPC
June 5th 2022The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.
Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma
Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.
177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel
June 5th 2022177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities
Ifosfamide Improves Survival vs Topotecan/Cyclophosphamide in R/R Ewing Sarcoma
Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.
Selpercatinib Demonstrates Promising Activity in RET Fusion-Positive Solid Tumors
June 5th 2022Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.
Zenocutuzumab was found to produce durable responses in patients with previously treated advanced NRG1-positive cancers, with antitumor activity observed across several tumor types, and to have an extremely well tolerated toxicity profile, according to data from a phase 1/2 trial (NCT02912949).
Liso-cel Elicits Significant Second-line Activity in Frail Patients with Relapsed/Refractory LBCL
June 5th 2022Treatment with lisocabtagene maraleucel resulted in a high rate of durable overall and complete responses as second-line therapy in frail patients with relapsed/refractory large B-cell lymphoma for whom hematopoietic stem cell transplantation was not intended, according to preliminary findings from the phase 2 PILOT study.
Panitumumab/mFOLFOX Establishes Prominent Role in RAS Wild-Type Metastatic CRC
The addition of panitumumab to mFOLFOX6 improved outcomes for patients with left-sided RAS wild-type metastatic colorectal cancer compared with bevacizumab and chemotherapy in the front-line setting, according to results from the phase 3 PARADIGM trial.
Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC
Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer.
Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma
June 5th 2022Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.
RVd Plus Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma
June 5th 2022The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.